NDNinel V. Dedukh

Ninel V. Dedukh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ninel V. Dedukh has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BIODEGRADABLE MAGNESIUM ALLOYS AS IMPLANTS FOR THE INTERVERTEBRAL DISC

    by K.M. Lytvynenko, N.V. Dedukh, O.A. Nikolchenko, K.V. Kutniy, M.A. Tikhonovsky

    Magnesium alloys are widely used in medicine, and the development of a new magnesium-based alloy with the required corrosion rate and antibacterial properties is a highly relevant task. It is known that silver (Ag) suppresses bacterial infection after implantation, due to the release of antimicrobial metal ions and the creation of an alkaline environment in the implant surroundings, which increases the effectiveness of the surgical intervention. The experimental study was carried out in compliance with the requirements of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (Strasbourg, 1986), Law of Ukraine No. 3447-IV of February 21, 2006 "On the Protection of Animals from Cruelty and the Humane Treatment of Experimental Animals". The operated spinal segment containing the implant was isolated, fixed in 10% neutral formalin and decalcified in formic acid. After passing through a series of alcohols (from 60 to 100°), it was embedded in celloidin. Sections were prepared on a Reichert microtome, stained with iron haematoxylin and eosin, as well as according to Van Gieson's method. The sections were examined using Olympus 33 BX and Axiostar Plus microscopes. In this study, three magnesium-based alloys were investigated, two of which were alloyed with silver. The alloys were specifically produced as part of a series of experimental studies involving in vivo implantation in rats. The purpose of this work was to study the structural features of the intervertebral disc after implantation of biodegradable magnesium-based implants in vivo. It was demonstrated that Mg alloys actively stimulated osteogenesis in vertebral bodies, accompanied by an increase in bone tissue density; the highest number of osteogenesis foci was observed at the implantation sites of the silver-alloyed rare-earth magnesium alloy WE43+1%Ag.

  • Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis

    by N. V. Grygorieva, V. M. Kovalenko, M. O. Кorzh, M. D. Tronko, I. Yu. Golovach, N. V. Dedukh, D. G. Rekalov, S. S. Strafun, S. I. Smiyan, O. A. Golubovska, et al.

    Introduction Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disorder caused by glucocorticoid (GC) use. It is one of the leading causes of secondary osteoporosis, increasing the risk of low-energy fractures, disability, and mortality. Although limited studies on GIOP epidemiology and treatment have been conducted in Ukraine, there were no national guidelines for its management. The aim was to create national guideline for the GIOP diagnosis, prevention, and treatment based on a comprehensive review of modern literature to enhance awareness within Ukraine’s medical community, improve disease management, and reduce its socio-economic impact. Materials and methods An Expert Group comprising 18 leading Ukrainian scientists from various fields was created for guideline development. A review of modern literature on GIOP epidemiology, risk factors, diagnosis, prevention, treatment, and monitoring was conducted. Evidence synthesis followed the GRADE methodology, and the quality of recommendations was critically evaluated using the AGREE II tool. Results The guideline comprises 12 statements covering GIOP screening, diagnosis, prevention, and treatment. We highlight the need to raise awareness among healthcare providers and patients about the potential effects of GC therapy. Also, we outline approaches to clinical assessment of osteoporotic fracture risk in GC users and detail diagnostic and therapeutic methods currently available in Ukraine for managing GIOP. Conclusion The first Ukrainian national GIOP guideline is critical for healthcare providers across specialities. Endorsed by the Board of the Ukrainian Association of Osteoporosis, it is recommended for use in routine clinical practice to enhance patient outcomes and mitigate the disease’s impact.


  • Open Access

    Ukrainian guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis

    by N.V. Grygorieva, V.M. Kovalenko, М.о. Коrzh, Tronko, I.YU. Golovach, N.V. Dedukh, D.G. Rekalov, S.S. Strafun, S.I. Smiyan, O.A. Golubovska, et al.

    Introduction. Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disease that develops as a result of glucocorticoid (GC) use, is one of the most frequent causes of secondary osteoporosis, leads to an increase in the risk of low-energy fractures, disability and mortality of GC users. Despite the few stu­dies conducted in Ukraine on the epidemiology and treatment of GIOP, there have been no national recommendations for its ma­nagement until now, which has become the background for their creation. The purpose was to develop national guidelines for the diagnosis, prevention, and treatment of GIOP based on the analytical analysis of modern literary sources to improve the awareness of the medical community of Ukraine, improve management, and reduce the socio-economic burden of the disease. Materials and ­methods. A group of 18 experts, leading Ukrainian scientists in various fields, was created to develop the guideline. An analysis of current literary sources on epidemiology, risk factors, diagnosis, prevention and treatment of GIOP, and monitoring of the effectiveness and safety of its treatment was carried out. Evidence was synthesized ­using the GRADE system, and a critical assessment of the quality of the recommendations was carried out using the AGREE II tool. ­Results. The guideline consists of 12 provisions on screening, diagnosis, prevention, and treatment of GIOP. The authors emphasized the need to increase the awareness of the medical community of Ukraine regarding the problem, as well as patients regarding the possible side effects of GC. They presented the features of the clinical assessment of the osteoporotic fracture risk in GC users, as well as modern and available in Ukraine methods of diagnosis and treatment of GIOP. Conclusion. The first Ukrainian guideline for screening, diagnosis, prevention, and treatment of GIOP is an important national tool for its management, which is recommended by the Board of the Ukrainian Association of Osteoporosis for use in practical health care by doctors of various specialties.


  • Open Access

    Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults

    by Nataliia Grygorieva, Mykola Tronko, Volodymir Kovalenko, Serhiy Komisarenko, Tetiana Tatarchuk, Ninel Dedukh, Mykola Veliky, Serhiy Strafun, Yulia Komisarenko, Andrii Kalashnikov, et al.

    Vitamin D deficiency (VDD) is a global problem, however, there were no Ukrainian guidelines devoted to its screening, prevention, and treatment, which became the reason for the Consensus creation. This article aimed to present the Consensus of Ukrainian experts devoted to VDD management. Following the creation of the multidisciplinary Consensus group, consent on the formation process, drafting and fine-tuning of key recommendations, and two rounds of voting, 14 final recommendations were successfully voted upon. Despite a recent decrease in VDD prevalence in Ukraine, we recommend raising awareness regarding VDD’s importance and improving the strategies for its decline. We recommend screening the serum 25-hydroxyvitamin D (25(OH)D) level in risk groups while maintaining a target concentration of 75–125 nmol/L (30–50 ng/mL). We recommend prophylactic cholecalciferol supplementation (800–2000 IU/d for youthful healthy subjects, and 3000–5000 IU/d for subjects from the risk groups). For a VDD treatment, we recommend a short-term administration of increased doses of cholecalciferol (4000–10,000 IU/d) with 25(OH)D levels monitored after 4–12 weeks of treatment, followed by the use of maintenance doses. Additionally, we recommend assessing serum 25(OH)D levels before antiosteoporotic treatment and providing vitamin D and calcium supplementation throughout the full course of the antiosteoporotic therapy.


  • Open Access

    Guideline for diagnostic, prevention and treatment of postmenopausal osteoporosis

    by N.V. Grygorieva, V.M. Kovalenko, М.о. Коrzh, T.F. Tatarchuk, N.V. Dedukh, S.S. Strafun, Z.M. Dubossarska, G.O. Protsenko, A.V. Kalashnikov, А.S. Musiіenko, et al.

    Background. Postmenopausal osteoporosis (PMO), which is developed due the estrogen defi ciency in women after menopause, is the most common type of systemic osteoporosis. The latest Ukrainian recommendation for its management requires revision due to new data from high-quality research performed in recent years. The purpose was to develop a guideline on the diagnosis, prevention, and treatment of PMO based on an analytical analysis of modern literary sources in order to improve the awareness of the medical community of Ukraine. Methodology. To develop the guideline, an expert group of 13 leading Ukrainian scientists of various specialties was created who conducted a tho rough review of modern literature on this topic, assessed the level of existing evidence using the GRADE system, proposed and voted on 15 recommendations of the guideline. Results. The guideline contains chapters on diagnosis and diff erential diagnosis of PMO, assessment of the osteoporotic fracture risk, the role of bone turnover markers in the management of PMO, and modern strategies of antiosteoporotic treatment. Conclusions. The Ukrainian guideline on the diagnosis, prevention, and treatment of PMO, which contains 15 main recommendations, created on the basis of a tho rough analysis and synthesis of modern literature data, is an important tool for the management of PMO and is recommended by Ukrainian Association of Osteoporosis for use in Ukrainian me dical community.


  • Open Access

    Diagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement

    by N.V. Grygorieva, M Tronko, V.M. Kovalenko, S.V. Komisarenko, T.F. Tatarchuk, N.V. Dedukh, M.M. Veliky, S.S. Strafun, Y.I. Komisarenko, A.V. Kalashnikov, et al.

    Background. Vitamin D deficiency (VDD) is widespread in the world; its proportion varies considerably in different populations and depends on many causes. Up to now, there were no National recommendations for the diagnosis, prevention, and treatment of VDD in adults in Ukraine. Their creation became the purpose of this work. Methodology. Consensus was created using the Delphi method, voting was conducted using the SurveyMonkey® platform. After approval of the composition of the Consensus Group, agreement on the order of formation and structure of the Consensus, creation and correction of the main statements, and two voting rounds, the main Consensus statements were formed and were successfully voted on. The 15 authors of the article are 15 experts who participated in the voting. The final 14 Consensus statements are presented in this article. Each statement is preceded by a justification based on high-quality evidence available in the current literature. Results. Despite the reduction of VDD in the Ukrainian population in recent years, experts have recommen­ded increasing the awareness of the medical community and the Ukrainian population about the problem and ways to overcome it, with a screening of the total serum level of 25-hydroxyvitamin D (25(OH)D) in subjects from the groups of risk to achieve the target concentration of 30–50 ng/ml (75–125 nmol/l). To ensure it, we recommend the individual selection of a prophylactic dose of vitamin D (800–2000 IU/d for young healthy persons and 3000–5000 IU/d for patients with diseases and conditions that affect the metabolism of vitamin D). For the treatment of VDD, we recommend short-term intake of higher doses (4000–10,000 IU/d) of vitamin D with control of the 25(OH)D level after 4–12 weeks of treatment and subsequent use of maintenance doses. Also, we re­commend the determination of serum 25(OH)D level before the initiation of antiosteoporotic therapy in patients with osteoporosis and its complications to prevent its ineffectiveness and increase the safety profile.


  • Open Access

    Effect of alfacalcidol on bone regeneration in senile rats

    by F.V. Klymovytskyy, V.G. Klymovytskyy, N.V. Dedukh

    Background. Among the drugs that have a pleiotropic effect on bone, attention is drawn to alfacalcidol – the precursor of the active form of D-hormone. There are studies that have revealed distinctive features of the effect of alfacalcidol on bone regeneration in osteoporosis and in young animals. The purpose was to study bone regeneration after treatment with alfacalcidol in senile animals. Materials and methods. A transcortical defect from the lateral to the medial femur was modeled in rats aged 24 months in the area of the metadiaphysis. A treatment with alfacalcidol was carried out from the 2-nd day and for 10 and 30 days before the animals was withdrawn from the experiment. Histological study of bone regeneration with morphometric analysis of tissues in the areas of callus had been performed. Results. On the 10-th day of the treatment with alfacalcidol in senile animals, connective tissue, osteoid and coarse-fibrous trabecular bone with a high density of osteoblasts were located in the defect area. On the 30-th day in treated animals, the bone tissue of the callus was mature; its area was larger than in untreated animals. In the area of cancellous bone there is a network of newly formed bone trabeculae. Destructive manifestations around the defect were reduced in animals treated with alfacalcidol. In untreated animals there was no dense bone fusion with cortex fragments; trabeculae of cancellous bone were intermittent. In the lateral part of the callus, the area of bone tissue was reduced compared to the medial part. Conclusions. Treatment of animals with alfacalcidol accelerates the formation of bone tissue in the defect and reduces destructive manifestations around the defect compared to untreated animals.

  • Open Access

    Disuse (post-mobilization) osteoporosis: literature review and clinical case series

    by N.V. Grygorieva, N.V. Dedukh, M.M. Parubets, M.A. Bystrytska

    Background. Disuse (рost-immobilization) osteoporosis is defined as secondary loss of bone mass in case of the absence or insufficient mechanical load on the skeleton. This disease can be associated with various risk factors, including long-time bed rest. The purpose of the research was to analyze modern literary data on the mechanisms of development, principles of diagnosis and treatment of disuse osteoporosis and to present own clinical data of disuse osteoporosis in the patients with multiple injuries of the skeleton in the conditions of war in Ukraine. Materials and methods. The review was based on the analysis of literature sources from the PubMed, WOS, Scopus, Google, Google Scholar, Cochrane Library databases for the years 2007–2022. The search was conducted using keywords: disuse osteoporosis, immobilization, bed rest, bone mineral density (BMD), bone remodeling, regeneration. Results. The data on the theory of the mechanostat are considered as links in the appearance of disuse osteoporosis. In conditions of immobilization, bone remodeling processes are slowing down. Histomorphometric studies confirm a decrease in trabecular bone density, thickness of the cortical layer, and an increase in its porosity. A change in bone architecture with a biphasic course is observed. Disruption of the synchronicity of remodeling processes with a decrease in the rate of osteoblastogenesis and an increase in osteoclastogenesis was noted, and the role of osteocytes as mechanosensors was emphasized. Disuse osteoporosis leads to a violation of biochemical marker of bone metabolism. Early laboratory manifestations of bed rest were recorded in the form of a violation of calcium level, an increase in bone resorption markers, while bone formation markers did not change significantly. Bone loss in disuse osteoporosis is manifested by a decrease in BMD indices. The greatest decrease was recorded in the lower extremities’ bones and the vertebrae of the lumbar spine. Modern methods of treatment of disuse osteoporosis involve the use of antiresorptive and osteoanabolic agents but clinical data are limited, which requires multicenter randomized studies. The article presents 3 clinical examples of disuse osteoporosis after gunshot fractures of the lower extremities’ bones.


  • Open Access

    Calcium-phosphate ceramics in spine surgery: features of regeneration and use

    by V.S. Shapovalov, N.V. Dedukh, M.V. Shymon

    The review is based on the analysis of 53 literature sources from PubMed, Google, Google Scholar, and Cochrane Library. Among the substitutes for autogenous bone grafts in spine surgery, ceramic biomaterials are the largest studied group, among which certain niche is occupied by calcium phosphate ceramics (CPCs). Hydroxylapatite, tricalcium phosphate and biphasic ceramics with all parts of hydroxylapatite and tricalcium phosphate are widely used in spine surgery. The advantage of using CPCs is their biocompatibility, osteoconductivity, osteoinductivity, osteoimmunomodulation and the ability to stimulate angiogenesis — the main components that ensure bone regeneration. In the given review, the peculiarities of regeneration in the interface “ceramic material — bone tissue” depending on the composition, surface structure, and crystallinity of the material are noted. The positive results of the experimental studies led to the use of CPCs in the clinic. CPCs with autogenous bone grafts are successfully used in posterior and posterolateral lumbar spondylodesis, which allows reducing significantly the volume of autologous bone. A new direction is the development of non-metallic combined cages, which are used to perform anterior cervical discectomy and spondylodesis. The composition of these cages includes various polymers in combination with CPCs and bone autogenous graft to ensure high-quality spondylodesis, reduce of stress-shielding and subsidence of the cage. A special approach requires the study of degradation and resorption by osteoclasts of various CPCs in order to control and synchronize the process of “resorption — bone formation”. Among the issues for the further research, the molecular mechanisms of osteoimunomodulation and factors that stimulate osseointegration and osteoinduction in the management of reparative osteogenesis should be further explored.

  • Open Access

    Sarcopenia, sarcopenic obesity and osteoarthritis

    by Ninel Dedukh, Nataliia Zaverukha, Maryna Bystrytska, Nataliya Yakovenchuk

    Sarcopenia is considered an important geriatric syndrome, the manifestations of which lead to impaired quality of life and increased mortality. Sarcopenia is a disease associated with decreased muscle mass and strength. Sarcopenic obesity is manifested by an increase in subcutaneous or visceral fat, fatty degeneration of muscles, and is also accompanied by impaired muscle function. After the age of 40, an average of 8 % loss of muscle mass is noted, and by the age of 80 this value can reach 50 %. The review examined the relationship between sarcopenia, sarcopenic obesity, and osteoarthritis (OA).Many exogenous and endogenous factors influence the development and course of OA. Based on the study of mechanisms of cellular and molecular profiles, the specific features for these frequently coexisting pathologies have been identified. The review presents the molecular mechanisms in the development of sarcopenia, sarcopenic obesity and osteoarthritis. Increased fat mass is manifested by increased adipogenesis, expression of inflammatory molecules (leptin, adiponectin, interleukin-1 (IL-1), IL-1b, IL-6 and tumor necrosis factor α) that contribute to chronic low-grade systemic inflammationand negatively affect muscle and joint quality. The relationship between elevated levels of myostatin and muscle weakness as well as myostatin accumulation in synovial fluid and severity of osteoarthritis was considered. Some common mechanisms in the development of sarcopenia and OA were noted: the influence of oxidative stress, systemic chronic inflammation, and disruption of the signaling pathway of bone morphogenetic proteins. Based on the analysis of associations between sarcopenia, sarcopenic obesity, and OA, population-based studies have revealed a high prevalence of knee OA with an increased risk among men with sarcopenic obesity. Women with sarcopenia and sarcopenic obesity had a high risk of knee OA in both groups. The review reviewed the prevention and treatment of the combined pathology, in particular the effect of sarcopenia on the results of total joint а rthroplasty in patients with OA. In general, sarcopenia, sarcopenic obesity, and OA can be considered as concomitant age-associated diseases that jointly affect quality of life and life expectancy.